Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment

We present a case of severe bowel perforation during lenvatinib treatment for advanced hepatocellular carcinoma. Although the Hartmann's procedure was performed, the patient died 48 h after the operation. The histopathological findings suggested that lenvatinib was involved in the etiology of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizokami, Ken, Watanabe, Akiko, Yamaguchi, Eriko, Saito, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459524/
https://www.ncbi.nlm.nih.gov/pubmed/36157608
http://dx.doi.org/10.1159/000525569
_version_ 1784786530470985728
author Mizokami, Ken
Watanabe, Akiko
Yamaguchi, Eriko
Saito, Akira
author_facet Mizokami, Ken
Watanabe, Akiko
Yamaguchi, Eriko
Saito, Akira
author_sort Mizokami, Ken
collection PubMed
description We present a case of severe bowel perforation during lenvatinib treatment for advanced hepatocellular carcinoma. Although the Hartmann's procedure was performed, the patient died 48 h after the operation. The histopathological findings suggested that lenvatinib was involved in the etiology of bowel perforation in this case.
format Online
Article
Text
id pubmed-9459524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-94595242022-09-23 Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment Mizokami, Ken Watanabe, Akiko Yamaguchi, Eriko Saito, Akira Case Rep Gastroenterol Single Case We present a case of severe bowel perforation during lenvatinib treatment for advanced hepatocellular carcinoma. Although the Hartmann's procedure was performed, the patient died 48 h after the operation. The histopathological findings suggested that lenvatinib was involved in the etiology of bowel perforation in this case. S. Karger AG 2022-08-29 /pmc/articles/PMC9459524/ /pubmed/36157608 http://dx.doi.org/10.1159/000525569 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Mizokami, Ken
Watanabe, Akiko
Yamaguchi, Eriko
Saito, Akira
Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title_full Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title_fullStr Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title_full_unstemmed Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title_short Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
title_sort bowel perforation in a patient with hepatocellular carcinoma during lenvatinib treatment
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459524/
https://www.ncbi.nlm.nih.gov/pubmed/36157608
http://dx.doi.org/10.1159/000525569
work_keys_str_mv AT mizokamiken bowelperforationinapatientwithhepatocellularcarcinomaduringlenvatinibtreatment
AT watanabeakiko bowelperforationinapatientwithhepatocellularcarcinomaduringlenvatinibtreatment
AT yamaguchieriko bowelperforationinapatientwithhepatocellularcarcinomaduringlenvatinibtreatment
AT saitoakira bowelperforationinapatientwithhepatocellularcarcinomaduringlenvatinibtreatment

Ejemplares similares